Εξειδίκευση τύπου :	Άρθρο σε επιστημονικό περιοδικό
Τίτλος:	Estrogen receptor beta 2 is associated with poor prognosis in estrogen receptor alpha-negative breast carcinoma
Δημιουργός/Συγγραφέας:	Chantzi N.I. Tiniakos D.G. Palaiologou M. Goutas N. Filippidis T. Vassilaros S.D. Dhimolea E. [EL] Μήτσιου, Δήμητρα[EN] Mitsiou, Dimitra J. [EL] Αλέξης, Μιχαήλ Ν.[EN] Alexis, Michael N.
Ημερομηνία:	2013
Γλώσσα:	Αγγλικά
ISSN:	0171-5216
DOI:	10.1007/s00432-013-1467-4
Άλλο:	PubMed ID: 23817696
Περίληψη:	Our aim was to examine the prognostic significance of ERbeta1 and ERbeta2 expression in ERalpha-negative breast carcinomas. Materials and methods: We evaluated nuclear and cytoplasmic expression of ERbeta1 and ERbeta2 by immunohistochemistry in a group of 95 patients with long follow-up. ERbeta1 and ERbeta2 status was correlated with clinicopathological parameters and disease outcome. Univariate and multivariate analyses of ERbeta1 and ERbeta2 as independent markers of disease-free survival (DFS) were carried out using the Cox proportional hazards model. Results: Nuclear ERbeta1 (nERbeta1) and nERbeta2 status was positively correlated (p = 0.01). nERbeta1 positivity was associated with low histological grade (p = 0.01) in all patients and in the nERbeta2-positive subgroup (p = 0.03) but not in the nERbeta2-negative (p = 0.27). nERbeta2 positivity was associated with lymph node involvement and tumor relapse in all cases (p < 0.00 and p < 0.00, respectively) and in the nERbeta1-negative subgroup (p < 0.00 and p < 0.00, respectively) but not in the nERbeta1-positive (p = 0.09 and p = 0.20, respectively). nERbeta2 positivity was associated with poor DFS in all patients (log-rank p <0.00), in the post-menopausal patient subgroup (log-rank p = 0.02) and in the HER2-negative (triple-negative) subgroup (log-rank p = 0.04). Cox multivariate analysis including ERbeta1, ERbeta2 and established clinicopathological variables highlighted ERbeta2 as an independent marker of early disease recurrence (hazard ratio 4.87; 95 % confidence interval 1.07-22.3; p = 0.04). Conclusion: High nERbeta2 is an independent marker of early relapse in ERalpha-negative breast carcinoma, and in particular, in the nERbeta1-negative, the post-menopausal patient and the triple-negative subgroups. These findings suggest that inhibition of expression and/or function of ERbeta2 could improve disease outcome.
Τίτλος πηγής δημοσίευσης:	Journal of Cancer Research and Clinical Oncology
Τόμος/Κεφάλαιο:	139
Τεύχος:	9
Σελίδες:	1489-1498
Θεματική Κατηγορία:	[EL] Θεραπευτική. Φαρμακολογία[EN] Therapeutics.Pharmacology [EL] Βιοχημεία[EN] Biochemistry
Λέξεις-Κλειδιά:	Breast cancer prognosis Estrogen receptor β2 Immunohistochemistry
Αξιολόγηση από ομότιμους (peer reviewed):	Ναι
Κάτοχος πνευματικών δικαιωμάτων:	© 2013 Springer-Verlag Berlin Heidelberg.
Σημειώσεις:	85355; 03ED644. This research has been supported by EU European Social Fund and Greek national funds through the Operational Program ‘‘Education and Lifelong Learning’’ of the NSRF-Research Funding Program: Projects THALES 85355 and by the Greek Ministry of Development through grant 03ED644.
Εμφανίζεται στις συλλογές:	Ινστιτούτο Χημικής Βιολογίας - Επιστημονικό έργο